The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2022Perspective and Consensus on Prevention Planning for Parkinson’s Disease
Study Rationale: In October 2022, a conference on “Planning for Prevention of Parkinson's: A trial design forum” gathered a broad range of stakeholders interested in preventing Parkinson’s disease (PD...
-
Accelerating the Translation of Parkinson's Disease Therapies, 2022Testing Small Molecules that Activate Removal of Cellular Debris for the Treatment of Parkinson’s Disease
Study Rationale:
People with Parkinson’s disease (PD) exhibit a diminished ability to remove cellular trash — including old and damaged molecules and organelles — from the brain. This impairment is... -
Research Grant, 2022LEARN-ATMP – Using the Patient Voice to Develop a Framework for Accessible ATMP Trials
Study Rationale: New therapies for Parkinson’s disease (PD) that involve the use of cells or genes — sometimes called advanced therapy medicinal products (ATMP) — are being developed and tested in...
-
Accelerating the Translation of Parkinson's Disease Therapies, 2022Esya PD360: A Multi-parametric Platform for Establishing a Novel Lysosome-based Biomarker and Identifying Therapeutic Interventions for Parkinson’s Disease
Study Rationale: Lysosomes are sub-cellular compartments responsible for clearing proteins that are prone to aggregation, a process called autophagy. Dysfunctional lysosomes with increased acidity and...
-
Summer 2022 RFP: Accelerating the Translation of Parkinson's Disease Therapies, 2022Validation of a Novel Mitochondrial Drug Target for Parkinson’s Disease
Study Rationale: Mitochondria provide cells with energy, but they also help regulate the flow of large amounts of calcium ions that flood neurons when they are active. In Parkinson’s disease (PD)...
-
Spring 2022 RFA: Target Advancement Program - Target Validation, 2022Evaluating an Insulin-degrading Enzyme as a Novel Therapeutic Target for Parkinson’s Disease
Study Rationale: In Parkinson’s disease (PD), the clumping of the protein alpha-synuclein in the brain causes the death of neurons. Recent studies have shown that the insulin-degrading enzyme (IDE)...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.